Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of remibrutinib in severe chronic pruritus of unknown origin
2025-524497-41-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in chronic idiopathic pruritus comparing Remibrutinib with Placebo (2 arms). Primary endpoint: WI-NRS responder rate at Week 12. Planned start Oct 2026; status: authorised.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic pruritus
Beyond the preview
Go deeper on 2025-524497-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524497-41-00.